Fig. 3
Expression levels of MYLK2 based on hormone receptor and clinical parameters. (A) Boxplot indicating MYLK2 expression (log2(TPM + 1)) in estrogen receptor (ER) negative versus positive samples, with significant differences marked (***p < 0.001). (B) Similar analysis for progesterone receptor (PR) status, showing significant elevation in MYLK2 expression in positive cases (***p < 0.001). (C) MYLK2 expression comparison between HER2 negative and positive statuses, with no significant difference observed. (D) Expression stratified by PAM50 subtypes, highlighting significant variations among normal, Luminal A, Luminal B, HER2, and Basal subtypes (*p < 0.05; ***p < 0.001). (E) Comparison of MYLK2 expression across pathologic N stages (N1, N2, N3), indicating significant differences between stages (**p < 0.01).
